[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605275":3},{"organization":4,"outcomesModule":7,"designInfo":47,"detailedDescription":46,"studyPopulation":46,"armGroups":56,"interventions":75,"overallOfficials":46,"centralContacts":85,"locations":91,"responsibleParty":118,"collaborators":46,"id":120,"slug":46,"hasResults":121,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":46,"eligibilityCriteria":125,"healthyVolunteers":126,"sex":127,"minAge":128,"maxAge":129,"enrollmentInfo":130,"targetDuration":46,"studyType":133,"phases":134,"briefSummary":136,"conditions":137,"keywords":46,"overallStatus":94,"whyStopped":46,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":148},{"fullName":5,"class":6},"Innovent Biologics Technology Limited (Shanghai R&D Center)","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":23,"otherOutcomes":46},[9,13,15,18,19,22],{"measure":10,"description":11,"timeFrame":12},"Number of Participants with adverse events (AEs)","An adverse event (AE) is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.","Part A: Baseline up to Day 15",{"measure":10,"description":11,"timeFrame":14},"Part B: Baseline up to Day 43",{"measure":16,"description":17,"timeFrame":12},"Number of Participants with One Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug","A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module.",{"measure":16,"description":17,"timeFrame":14},{"measure":20,"description":21,"timeFrame":12},"Number of Participants with More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug","A summary of other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.",{"measure":20,"description":21,"timeFrame":14},[24,28,31,33,34,36,37,39,40,42,43,45],{"measure":25,"description":26,"timeFrame":27},"Under the Serum Concentration-time Curve (AUC) of IBI3032","To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.","Part A: Predose up to 168 hours postdose",{"measure":25,"description":29,"timeFrame":30},"To evaluate the pharmacokinetic (PK) characteristics of multiple doses of IBI3032 in participants with overweight or obesity.","Part B: Predose up to 168 hours postdose",{"measure":32,"description":26,"timeFrame":27},"maximum concentration (Cmax) of IBI3032",{"measure":32,"description":29,"timeFrame":30},{"measure":35,"description":26,"timeFrame":27},"time to maximum concentration (Tmax) of IBI3032",{"measure":35,"description":29,"timeFrame":30},{"measure":38,"description":26,"timeFrame":27},"clearance (CL) of IBI3032",{"measure":38,"description":29,"timeFrame":30},{"measure":41,"description":26,"timeFrame":27},"apparent volume of distribution (V) of IBI3032",{"measure":41,"description":29,"timeFrame":30},{"measure":44,"description":26,"timeFrame":27},"elimination half-life (T1\u002F2) of IBI3032",{"measure":44,"description":29,"timeFrame":30},null,{"allocation":48,"interventionModel":49,"interventionModelDescription":46,"primaryPurpose":50,"observationalModel":46,"timePerspective":46,"maskingInfo":51},"RANDOMIZED","SEQUENTIAL","TREATMENT",{"masking":52,"maskingDescription":46,"whoMasked":53},"DOUBLE",[54,55],"PARTICIPANT","INVESTIGATOR",[57,63,68,72],{"label":58,"type":59,"description":60,"interventionNames":61},"Single dose of IBI3032 administered orally.","EXPERIMENTAL","Part A",[62],"Drug: IBI3032 tablets",{"label":64,"type":65,"description":60,"interventionNames":66},"Single dose of placebo administered orally.","PLACEBO_COMPARATOR",[67],"Drug: Placebo",{"label":69,"type":59,"description":70,"interventionNames":71},"Multiple doses of IBI3032 administered orally.","Part B",[62],{"label":73,"type":65,"description":70,"interventionNames":74},"Multiple doses of placebo administered orally.",[67],[76,81],{"type":77,"name":78,"description":79,"armGroupLabels":80,"otherNames":46},"DRUG","Placebo","Single dose placebo IBI3032 administered orally",[73,64],{"type":77,"name":82,"description":83,"armGroupLabels":84,"otherNames":46},"IBI3032 tablets","Single dose of IBI3032 administered orally",[69,58],[86],{"name":87,"role":88,"phone":89,"phoneExt":46,"email":90},"Dee Li","CONTACT","18017984650","dee.li@innoventbio.com",[92],{"facility":93,"status":94,"city":95,"state":96,"zip":97,"country":98,"countryCode":99,"cosmosGeoPoint":100,"geoPoint":105,"contacts":106},"Zhongshan Hospital affiliated to Fudan University","RECRUITING","Shanghai","Shanghai Municipality","200030","China","CN",{"type":101,"coordinates":102},"Point",[103,104],121.45806,31.22222,{"lat":104,"lon":103},[107,111,115,117],{"name":108,"role":88,"phone":109,"phoneExt":46,"email":110},"Xuening Li","021-31587862","li.xuening@zs-hospital.sh.cn",{"name":112,"role":88,"phone":113,"phoneExt":46,"email":114},"Xiaoying Li","021-31023402","li.xiaoying@zs-hospital.sh.cn",{"name":112,"role":116,"phone":46,"phoneExt":46,"email":46},"PRINCIPAL_INVESTIGATOR",{"name":108,"role":116,"phone":46,"phoneExt":46,"email":46},{"type":119,"investigatorFullName":46,"investigatorTitle":46,"investigatorAffiliation":46,"oldNameTitle":46,"oldOrganization":46},"SPONSOR","100605275",false,"NCT07160400","A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity","A Phase 1 Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032 After a Single Ascending Dose in Healthy Participants and After Multiple Ascending Doses in Participants With Overweight or Obesity","Inclusion Criteria:\n\n1. Male or female aged 18-65 years (inclusive) at the time of informed consent.\n2. Participants must understand the procedures and methods of this study, be willing to complete the study in strict accordance with the clinical study protocol, and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n1. The investigator suspects that the participant may be allergic to any component of the study drug or GLP-1 receptor agonists, or have used GLP-1 receptor agonists within 3 months prior to screening.\n2. History of diabetes, or HbA1c ≥ 6.5% and fasting blood glucose \\\u003C 3.9 mmol\u002FL or ≥ 7.0 mmol\u002FLat screening.\n3. Presence of any other abnormalities in vital signs and laboratory tests that are clinically significant as judged by the investigator at screening.",true,"ALL","18 Years","65 Years",{"count":131,"type":132},104,"ESTIMATED","INTERVENTIONAL",[135],"PHASE1","This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single ascending dose of IBI3032 in healthy participants and multiple ascending doses of IBI3032 in participants with overweight or obesity. It consists of 2 parts: Part A is a single ascending dose (SAD) study in healthy participants, and Part B is a multiple ascending dose (MAD) study in participants with overweight or obesity during the 4-week treatment period.",[138],"Part A: Healthy Part B: Overweight or Obesity","2026-04-07",{"date":141,"type":142},"2026-04-08","ACTUAL",{"date":144,"type":142},"2025-09-04",{"date":146,"type":132},"2026-09-30",{"name":5,"class":6},1]